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ABSTRACT
PREVENTION AND TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS AND
COLORECTAL CANCER BY BILBERRY-DERIVED ANTHOCYANIDINS
Ashley Marie Mudd
July 13th 2017
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths within the United
States. Familial adenomatous polyposis (FAP) is an inherited disorder which if left untreated will
develop into colon cancer. The family of plant-derived compounds, anthocyanins, show significant
therapeutic potential against a variety of diseases, however, they are limited by their instability and
poor bioavailability. The goal of my Master’s research project was to determine whether
anthocyanidins (non-glycosylated anthocyanins) are more effective than the native anthocyanins,
and whether exosomal formulation of anthocyanidins (ExoAnthos) can enhance therapeutic
potency compared with free Anthos against both FAP and CRC. The antiproliferative effects of the
native mixture of Anthos isolated from bilberry, with and without exosomal formulation, as well as
individual Anthos against APC mutant (HT-29, Caco2), APC wild-type (HCT116) colon cancer cells
and CCD-18Co normal colon cells were assessed using an MTT assay. To assess
chemopreventive effects, the impact of the Anthos on polyp number was investigated in the
APCMin/+ mouse model for FAP. While therapeutic efficacy of the Anthos treatment on colorectal
tumor number was assessed in vivo using an APCMin/+ ETBF mouse tumor model. Early
mechanistic work was undertaken to assess the impact of Anthos treatment on EGFR and Src
phosphorylation using western blot analysis. Antiproliferation studies showed that ExoAnthos
significantly lowered the IC50 compared to free Anthos against colon cancer cells. Anthos treatment
led to significant reductions in polyp and tumor counts in vivo. Reduced Src and EGFR
phosphorylation was also observed. These results provide a promising outlook on the future of the
berry Anthos for treatment and prevention for both FAP and CRC.
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BACKGROUND & INTRODUCTION
Colorectal cancer
Colorectal cancer is the third most common form of cancer diagnosed in men and women
and the third leading class for yearly cancer-related deaths within the United States.
According to the American Cancer Society, an estimated 135,430 individuals will be
diagnosed and 50,260 will die from colorectal cancer in the US in 2017 alone.
Furthermore, according to the SEER database, in 2014 an estimated 1,317,247
individuals were living with colorectal cancer in the United States. Given the prevalence
and lethality of colorectal cancer, there is a great need for investigating not only
chemotherapeutic alternatives but also chemopreventive strategies for this disease.
Influences on the development of colorectal cancer
A wide variety of influences have been found to impact an individual’s chance of
developing colorectal cancer including age, race, gender [1], lifestyle and diet [2]. The
highest incidence rates have been found in North America, Europe, Australia and New
Zealand and the lowest incidence rates have been found in Africa and South-Central Asia
[3]. Although the incidence of colorectal cancer has been decreasing since the mid to late
1980s for individuals over 55 years old, a recent study has found a rather disconcerting
uptick in the colorectal cancer incidence for individuals below 55 years old [4]. A
particularly concerning trend was noted for millennials, with individuals born circa 1990
having a risk of developing colon cancer that is double that of an individual born circa 1950
and for rectal cancer the risk was four fold higher. Moreover, a greater number of the
younger cases were found in the distal colon as opposed to the proximal colon. This is
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somewhat surprising considering that tumors in the distal colon have been decreasing
overall in recent years, while tumors of the proximal colon have become more common in
the 55 years or older portion of the population [4]. The exact causes for this recent increase
in younger individuals have yet to be defined. However, a number of factors have been
shown to contribute to the development of colorectal cancer. The below summary provides
an overview of some of the key environmental as well as genetic factors that are related
to the topic of this thesis and that have been found to impact the development of colorectal
cancer.
The impact of diet and lifestyle on CRC risk
The important role that diet and lifestyle play not only on one’s overall health but on the
chance of developing colorectal cancer has been found in a number of studies.
Furthermore, it should be noted that chronic inflammation has been shown to be a
significant etiological factor in the development of colorectal adenocarcinoma [5]. It has
been shown in both males and females that a link exists between consuming a high
inflammatory diet, i.e. a diet rich in animal fat, alcohol et cetera and low in fruits and
vegetables, and developing colorectal cancer [2]. Moreover, results from the same study
also supported the benefits of an anti-inflammatory diet, which include plant based foods
which are a rich source of phytochemicals, over a pro-inflammatory diet, which includes
fried foods, highly processed food etc., as a means of decreasing the risk of developing
CRC [2]. Additionally, coffee which contains a variety of bioactive compounds including
polyphenols, melanoidins, diterpenes, and caffeine is believed to also lower the risk of
developing CRC [6]. Epidemiological studies comparing coffee drinkers vs. non-drinkers
showed a 26% lower odds of developing CRC [6]. There also appeared to be a dose
dependent trend for both colon and rectal cancers. It was also noted that decaffeinated as
well as boiled coffee showed an inverse association (OR, 0.82; 95% CI: 0.68-0.99;
2

P=0.04) and (OR, 0.82; 95% CI: 0.71-0.94; P=0.004) respectively [6]. In addition to coffee,
it has also been shown that regular green tea consumption (at least three times per week
for a minimum of 6 months), which is a rich source of antioxidant tea polyphenols, reduces
the risk of colorectal cancer (HR=0.54, 95% CI: 0.34-0.86). Furthermore, it was noted that
as green tea consumption was increased risk of colorectal cancer decreased (Ptrend=0.01)
[7].
In addition to dietary influences, another important factor that must be considered is the
long term use of medications such as statins, aspirin and non-aspirin nonsteroidal antiinflammatory drugs which are also believed to lower the risk of developing CRC. For
example statins which are believed to inhibit 3-hydroxy-3methylglutaryl coenzyme A
(HMG-CoA) reductase which is overexpressed in colorectal cancer cells were associated
with a 47 percent relative reduction in risk of CRC [8]. Whereas, NSAIDS, which are
believed to act by inhibiting cyclooxygenase-2, which has been shown to be upregulated
in colorectal cancer, was shown to yield an adjusted relative risk of 0.5 (95% confidence
interval of 0.4-0.7) [9].
Great insight into the complex exchange between the individual and their surroundings
and their associated risk of developing colorectal cancer has been gained by the sheer
depth of epidemiological studies conducted to date. However, the above findings should
be interpreted with caution due to the dangers of inferring causation from association. The
above studies provide a promising foundation from which the topic of my thesis, i.e. the
use of anthocyanidins as both a chemotherapeutic as well as preventative agent, has been
constructed.
Outline of mutations found to be linked with development of CRC
In addition to the extrinsic influences discussed above, another key participant in the
dialogue of colorectal carcinogenesis is genetics. Some of the key genes that have been
3

found to influence the development of CRC include TP53, KRAS/BRAF [10, 11],
EGFR/PTEN [12-14], SMAD7 [15], MLH1 [16], MUTYH [17] and the adenomatous
polyposis coli (APC) gene [18-21].
Both sporadic and hereditary cases of colorectal cancer have been attributed to mutations
in the adenomatous polyposis coli (APC) gene. It has been noted that 34-70% of sporadic
colon cancer cases feature inactivating mutations in APC particularly in the mutation
cluster region, with genetic aberrations such as deletions, insertions, point and missense
mutations detected in the mutation cluster region in 72% of the patients studied [18]. It has
also been shown that individuals with APC gene mutations possess a significantly
increased risk for colorectal cancer (pooled OR of 1.42 and 95% CI of 1.16-1.74 with a P
value of 0.00085) [19]. Furthermore, it should be noted that APC mutations appear to be
more likely to occur with TP53 mutations (OR 3.513, 95% CI of 1.212-10.184) and KRAS
mutations (OR 1.995, 95% CI of 0.607-6.554) [21].
The important role that the above mutations, especially APC, play in the development of
CRC has been historically well documented. Moving forward, the characterization or
“fingerprinting” of an individual’s specific mutations will be key in developing personalized
therapeutic regimens for each patient.
Pathways of genomic instability that can lead to CRC
It is commonly accepted knowledge that three main molecular pathways of genomic
instability are involved in the development of CRC and include: the chromosomal instability
pathway (CIN), the mismatch repair deficient or microsatellite instability pathway (MSI),
and the CpG island methylator phenotype (CIMP) pathway.
The CIN pathway, which was originally elucidated by Fearon and Vogelstein in 1990, is
believed to be responsible for most cases of CRC and is observed in 65-70% of sporadic
4

CRC’s [22]. These cases feature characteristic loss of heterozygosity (LOH), subchromosomal genomic amplifications and widespread aneuploidy. In Fearon and
Vogelstein’s seminal 1990 article, they proposed a multistep model for colorectal
carcinogenesis [23] which is shown in Figure 1. The initiating event in adenoma formation
is the inactivation of the Adenomatous Polyposis Coli (APC) tumor suppressor gene which
is followed by activating mutations of KRAS. Additional mutations in TGF-β [24], PIK3CA
[25], and TP53 [26] pathways then drive the subsequent malignant transformation. It
should be noted that although APC mutations serve as the initiating event in human and
mouse models, mutational activation of KRAS is unable to initiate cancer in vivo and only
when combined with mutant APC will mutant KRAS promote tumor progression, thus
supporting Fearon’s multistep model [27].
The Microsatellite instability (MSI) pathway accounts for approximately 10-20% of all
CRCs [28]. Although the MSI pathway was originally elucidated for individuals with familial
Lynch syndrome, most CRCs with MSI are sporadic. In fact, only 3% of all CRCs come
from Lynch syndrome families [29]. MSI tumors caused by Lynch syndrome are
associated with germline mutations in DNA mismatch repair (MMR) genes and often have
KRAS mutations, but never have BRAF mutations.
Lynch syndrome tumors also typically occur in younger individuals and typically have a
better prognosis than non-MSI tumors [30]. Approximately 50% of sporadic cases of MSI
have BRAF mutations and are associated with CIMP, unlike Lynch syndrome tumors. As
can be expected, sporadic cases of MSI-associated CRCs typically occur in older
individuals[29].
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Figure 1: Adenoma-carcinoma sequence in the development of colorectal cancer
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The CpG island methylator (CIMP) is observed in approximately 30% of CRC cases [31].
As its name implies, the CIMP pathway promotes epigenetic instability and enables
sporadic cancers to methylate the promoter regions of key tumor suppressor genes
thereby effectively inactivating their expression [32]. In fact it is present in all tumors with
MLH1 aberrant methylation [33]. CIMP positive tumors typically exhibit specific
clinicopathological features such as proximal location and tend to be more common in
older women, are often MSI and poorly differentiated. They also tend to have a distinct
molecular profile which features low TP53 and high BRAF mutation rates [34].
Furthermore, cases of colorectal cancer that develop via the CIMP pathway tend to
develop from sessile serrated adenomas rather than adenomatous polyps [35].
Current standard of care
As with most cancers current treatment options for individuals diagnosed with colorectal
cancer include one or more of the following options: surgery, radiation therapy, nontargeted chemotherapy, or targeted therapy.
According to the American Cancer Society, drugs currently approved by the U.S. FDA for
the treatment of colorectal cancer include: capecitabine, fluorouracil (5-FU), irinotecan,
oxaliplatin, and trifluridine/tipiracil. One or more of these chemotherapeutic drugs are most
often given over the course of treatment with more common treatment regimens with these
drugs including: 5-FU, 5-FU with a vitamin called leucovorin which improves the efficacy
of 5-FU [36], capecitabine, 5-FU with leucovorin and oxaliplatin (FOLFOX), 5-FU with
leucovorin and irinotecan (FOLFIRI), capecitabine with either irinotecan (XELIRI or
CAPIRI) or oxaliplatin (XELOX or CAPEOX), and irinotecan alone. A variety of negative
side effects are associated with taking the standard chemotherapeutic drugs including:
nausea, vomiting, fatigue, diarrhea, suppression of bone marrow, immunosuppression,
and liver damage [37, 38]. Given the current limitations and negative side effects
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associated with the current standard of care, additional treatment options are greatly
needed.
In addition to non-targeted chemotherapeutic treatment options, targeted therapies are
also common, including: bevacizumab, regorafenib, ramucirumab and ziv-aflibercept,
which are antiangiogenesis therapies, and cetuximab and panitumumab which are antiEGFR therapies [39]. Although, one of the key benefits of targeted therapy is the reduction
in off-target side-effects, they are also accompanied with side-effects including
gastrointestinal perforation, arterial thromboses which include strokes and myocardial
infractions [40].
Treatment options for individuals diagnosed with colon cancer are typically dependent
upon their specific stage. Additional factors such as age and other health problems are
also considered for the optimal treatment plan [41]. In most cases, when the cancer has
not spread to distant sites, surgery is typically the first main treatment. For more advanced
stage cancers, an adjuvant chemotherapy may also be recommended. Adjuvant
chemotherapy may be recommended as early as stage II, but is more typically
recommended beginning in stage III [41]. For the more advanced stage IV cases of colon
cancer where the disease has spread to distant organs and tissues, a key component of
the treatment is chemotherapy since in most cases surgery will not cure these individuals.
Since the early 2000’s, 5 new drugs have been approved for the treatment of stage IV
colon cancer. These drugs fall into one of the three following classes: multi-kinase
inhibitors, anti-angiogenic (Bevacizumab, Ziv-aflibercept), or EGFR blockers (Cetuximab,
panitumumab) [42].
Key limitations in the current standard of care include, but are not limited to the following
areas: off-target side effects, the current gap that exists in adjuvant therapy for stage I and
especially stage II cancers of the colon, and limitations in treatment options for older
8

individuals. Given these limitations, research investigating alternative preventative
treatment options is of great importance.
Familial Adenomatous Polyposis (FAP)
The majority of colorectal cancer cases originate from previously benign adenomatous
polyps. This process of transformation from benign polyp to malignancy typically takes
decades to occur, with approximately 85% of colorectal cases occurring after the age of
55 years, according to data acquired by the U.S. preventive services task force. A small
subset of CRC cases stem from familial syndromes such as Lynch syndrome, FAP,
attenuated FAP (AFAP), MUTYH-associated polyposis (MAP) and rare syndromes such
as hyperplastic polyposis, Peutz-Jeghers syndrome (PJS) and juvenile polyposis
syndrome [43, 44].
FAP is an autosomal dominant pre-cancerous colorectal condition with an incidence at
birth of around 1/8,300 [45]. FAP occurs with equal frequency in both males and females
and accounts for less than 1% of colorectal cases [45]. The disease may begin as early
as the teenage years, with colon cancer developing on average by the age of 39 years
old. Furthermore, approximately 7% of individuals with FAP will develop CRC by the time
they reach 21 years old and 95% of FAP sufferers will develop CRC by the time they reach
the age of 50 [46]. FAP is caused by mutation(s) in the adenomatous polyposis coli (APC)
gene. The APC gene, which is located on chromosome 5q21 is a tumor suppressor gene
that encodes for a 312 kDa protein with 2843 amino acids. It is expressed in a variety of
fetal and adult tissues including colorectal epithelium as well as mammary [47].
Mutation(s) in the APC gene, 60% of which are nonsense mutations, have been shown to
accelerate the initiation of the adenoma-carcinoma sequence since the inactivation of APC
serves as the initial step in the development of CRC in FAP [45]. The APC protein serves
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as a scaffolding protein which affects cell adhesion and migration. The mammalian form
of APC contains multiple binding domains including an oligomerization domain, an
armadillo repeat domain, a repeat domain consisting of between 15-20 residues which is
important for binding to β-catenin, SAMP repeats which are important for axin binding, a
basic domain that is responsible for microtubule binding, and finally C-terminal domains,
which bind the proteins, EB1 and HDLG [48].
APC interacts with a variety of other key proteins such as the Wnt/Wg pathway members,
β-catenin and axin, the Rac guanine-nucleotide-exchange factor (GEF) Asef1, the
cytoskeletal regulators EB1 and IQGAP1, as well as microtubules [49]. Mutations in APC
lead to the accumulation of β-catenin in the cytoplasm where it binds and activates the Tcell factor (TCF) and lymphoid enhancer factor (LEF) families of transcription factors
altering the expression of genes that encode for the metalloprotease matrilysin, ephrins,
cyclin D1 and the proto-oncogene c-myc which in turn lead to changes in cellular
proliferation, differentiation and migration [50].
If left untreated, individuals with FAP will develop colorectal cancer by their forties [51]. As
discussed above, APC plays a key role in the multi-step model of colorectal cancer
proposed by Fearon and Vogelstein (Figure 1). The disease is characterized by the
development of hundreds to thousands of adenomatous colon polyps. Currently, the only
approved primary modality of treatment for FAP is prophylactic cancer-preventive
colorectal surgery. Given the lack of non-invasive treatment options and the role of FAP
in CRC development, additional treatment options are of great need.
Anthos: a promising treatment for FAP and colorectal cancer
Several plant-derived compounds such as quinine, codeine, paclitaxel, apomorphine,
have been an invaluable source of medicines for humans throughout history. One
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particular family of compounds that has sparked recent interest is flavonoids and members
such as anthocyanins.
Flavonoids
One particular class of relevance is the flavonoids which is one of the largest groups of
secondary metabolites with well over 6000 molecules [52]. Compounds classified as
flavonoids, which all share a common core 15-carbon skeleton, can be divided into 6 major
classes: flavanols, flavonols, flavonones, flavones, isoflavones and anthocyanins.
Flavonoids are commonly synthesized by plants in order to fulfil a variety of protective
functions ranging from as a chromatic attractant for pollinators, as a deterrent for pests,
as a protectant against UV-B, as well as an antimicrobial agent [53].
Anthocyanins and anthocyanidins
Found in dark-colored vegetables, fruits, grains and flowers, anthocyanins, which comes
from the Greek words Anthos for flower and kyanos for blue, provide the characteristic
red, purple and blue hues to eggplant, blueberry, black rice and black sesame seeds. Over
600 structurally distinct anthocyanins have been identified in nature [54, 55]. It should be
noted that anthocyanins are known as anthocyanidins when non-glycosylated. Of the
seventeen anthocyanidins found in nature, only six, including the glycosylated forms of:
cyanidin (Cy), delphinidin (Dp), petunidin (Pt), peonidin (Pn), pelargonidin (Pg) and
malvidin (Mv), are widely distributed [56]. The above anthocyanidins are typically bonded
to glucose, galactose, arabinose, rhamnose, and xylose in either a mono-, di- or trisaccharide form. An additional layer of complexity is provided by the fact that the sugar
moieties can also be acylated by various aromatic or aliphatic acids. The various
combinations/permutations of anthocyanidins and their pendant sugars vary from plant to
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plant. Importantly, it should be highlighted that the active component of the compounds is
the central anthocyanidin moiety.
The core structure of anthocyanidin (Figure 2) is composed of an aromatic ring A that is
bonded to a heterocyclic ring C containing oxygen that is bound via carbon to a third
aromatic ring B. The substituted flavonoids contain a flavylium cation, which due to its
conjugated double bonds, absorbs light with a characteristic peak range between 500550nm. The specific hue(s) associated with each anthocyanin depend upon the degree of
hydroxylation and type/number of substitutions. A total of 17 anthocyanidins have been
isolated to date [57].
The specific anthocyanin fingerprint varies between each type of fruit, vegetable, grain or
flower. For example fruits such as red currents and elderberry contain primarily cyanidin,
whereas blueberry, bilberry and jamun contain 5 anthocyanidins- cyanidin, delphinidin,
petunidin, peonidin and malvidin, all in their glycosylated forms. Bilberry in particular
contains a native mixture of delphinidin, cyanidin, malvidin, peonidin, and petunidin in a
relative ratio of 33:28:16:16:7 [58]. As noted above, in addition to variations in the core
anthocyanidin structure, variations in the pendant sugar moieties also varies from plant to
plant. For example, even though red currant and blackcurrant are closely related, red
currant contains mainly mono- and diglycosides, whereas black currant contains primarily
rutinosides and only a minor glycoside component [59].
Role of anthocyanins within plants
Within plants, anthocyanins accumulate in vacuoles of a variety of cells in both vegetative
as well as reproductive organs. Most of the 17 anthocyanidins isolated to date are found
only in the reproductive structures of the plants whereas only six anthocyanidins (cyanidin,
peonidin, delphinidin, petunidin, malvidin and pelargonidin) have been found in the
vegetative organs [60].
12
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contained in blueberry and bilberry
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Furthermore, anthocyanins are synthesized in the branch of the flavonoid biosynthetic
pathway that is involved in the synthesis of isoflavonoids and flavonols [57]. Anthocyanins
are thought to play a variety of different functions within plants ranging from as
antioxidants, sunscreens, and even as metal-chelating agents and in delaying foliar
senescence under conditions of mineral imbalance or macronutrient deficiency [57]. Given
their beneficial roles in plants, one can easily hypothesize that benefits may be gained
from their consumption by humans.
Anthocyanin absorption, stability, and digestion
Absorption of anthocyanidins and anthocyanins by gut epithelial cells occurs via different
mechanisms due to the structural differences. Due to the hydrophilicity added by the sugar
residues on anthocyanins they must utilize active transport mechanisms whereas
anthocyanidins, which do not have a sugar residue and are more hydrophobic are able to
be passively absorbed by gut epithelial cells [61]. In fact, the hydrophobicity of a
compound, expressed in terms of its partition coefficient (log octanol/water) is often used
as a predictive means to determine the ability of a compound to passively diffuse across
a biological membrane. Interestingly, it has been found that nonenzymatic deglycosylation
does not occur in the human body for polyphenols such as quercetin [62]. Additionally,
only polyphenols with attached glucose, arabinose or xylose and not rhamnose moieties
can serve as potential substrates for human β-glucosidases. Therefore, rhamnose
moieties can only be cleaved once they reach the colon where they can serve as a
substrate for bacterial α-rhamosidases [61]. This limitation may have important
ramifications for the activity of rhamnose-containing anthocyanins in diseases of the small
intestine or in diseases where digestive transport time is expedited such as inflammatory
bowel disease (IBD).
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Another important topic that must be addressed in the discussion of anthocyanin
metabolism is the role of deconjugation and reconjugation reactions. Although
anthocyanins do not appear to undergo as extensive of metabolism as other flavonoids, it
will be discussed for completion since it occurs and is a variable that must be considered
[63]. Following hydrolysis, the free aglycones undergo metabolic processing in the form of
methylation, sulfation, glucuronidation or a combination of the above reactions [64, 65].
Based on the structural differences between anthocyanins versus anthocyanidins, the
impact that conjugation has on the biological properties of the circulating metabolites is
evident.
Overall, one should understand that a competition between the uptake of anthocyanidins
and the excretion of more hydrophilic anthocyanins as well as their conjugated
counterparts exists. Therefore, one could posit that by administering anthocyanidins either
in their pure form or by nano-delivery systems, one would enhance their therapeutic
potential in the clinical setting.
Data from In vitro work
A variety of in vitro studies have been conducted in order to investigate the impact that
anthocyanins derived from various sources have on colon cancer cell lines. Berry extracts
containing anthocyanins isolated from cowberry, strawberry, bilberry, and blueberry have
been shown to inhibit the proliferation of the colon cancer cell line HCT116 [66].
Furthermore, anthocyanin rich extracts derived from fruits including bilberry (Vaccinium
myrtillus L.), grape (Vitis vinifera), and chokeberry (Aronia meloncarpa E.) have been
shown to inhibit the growth of the colon cancer cell line HT-29 cells but not the nontumorigenic NCM460 colon cells [67].
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A variety of potential mechanisms have been suggested in the literature. For instance,
anthocyanins isolated from the grape, Vitis coignetiae Pulliat were shown to induce
caspase-dependent apoptotic cell death, activate p38-MAPK and suppress Akt in HCT116 colon cancer cells [68]. Moreover, pelargonidin, found in a variety of berries such as
strawberries and pomegranates, was shown to inhibit proliferation of the colon cancer cell
line HT-29 and induce apoptosis and G2/M cell cycle arrest by the intrinsic apoptotic
pathway [69]. Additionally, delphinidin, found in fruits like blueberry, has also been shown
to induce apoptosis and G2/M cell cycle arrest in HCT116 colon cancer cells [70]. The
mechanism by which delphinidin led to G2/M arrest and apoptosis in HCT116 cells is
believed to be due to suppression of the NF-κB pathway [70]. Anthocyanins and
anthocyanidins have also been shown to induce significant oxidative DNA-strand
cleavage in the presence of dithiotheritol (DTT), but not DMSO, which serves as a free
radical scavenger, at physiological pH. It was further hypothesized that at pH 7.5, the
quinones formed from anthocyanins and anthocyanidins autoxidize to yield hydrogen
peroxide [71]. Fe 3+ is believed to increase anthocyanin-induced cleavage since when it is
reduced it is able to stimulate the production of hydroxyl radicals from hydrogen peroxide.
The resulting hydroxyl radical, rather than hydrogen peroxide, is believed to induce the
cleavage of DNA [71]. Only at high concentrations were anthocyanins also shown to inhibit
topoisomerase relaxation [71].
Data from in vivo studies
The beneficial effects of anthocyanins shown in vitro have also been shown to exist in
vivo. For instance, the anthocyanin-rich soybean fraction containing cyanidin-3-glucoside,
delphinidin-3-glucoside and petunidin-3-glucoside, was shown to significantly decrease
the number of intestinal tumors in ApcMin/+ mice fed a 0.5% anthocyanin-rich extract
compared to control animals [72]. Furthermore, mucosal expression of cytosolic
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phospholipase A2 and cyclooxygenase-2, which are both involved in inflammatory
response, were significantly decreased in mice treated with 0.5% anthocyanin-rich extract
[72]. Additionally, an in vivo study in ApcMin/+ mice using 0.3% oenocyanin, which contains
the 3-glucosides of delphinidin, cyanidin, petunidin, peonidin, and malvidin extracted from
grape pomace, showed a reduction in adenoma burden and reduction in proliferation index
in colonic adenomatous crypts [73]. A reduction in the expression of Akt, which is involved
in a variety of cellular processes including glucose metabolism, apoptosis, cellular
proliferation, transcription and migration, was also observed in 0.3% oenocyanin-treated
mice [73]. Interestingly, oenocyanin anthocyanins and their metabolites were not found in
the plasma but rather only in the urine and intestine [73]. Moreover, in a mouse model of
colitis, dextran sulfate sodium (DSS) induced histological damage and weight loss were
significantly improved in mice administered a red raspberry anthocyanin-rich fraction [74].
In the same study, anti-inflammatory properties were shown in vivo with overall reductions
in the expression of cyclooxygenase-2 (COX-2), interleukin-1 beta (IL-1β), IL-6 and
inducible nitric oxide (iNOS) in red raspberry anthocyanin-rich fraction treated RAW264.7
cells [74].
A study assessing the impact of dietary cyanidin-3-glucoside and an anthocyanin mixture
from bilberry on the development of adenomas in an ApcMin/+ mouse model for FAP [75]
showed that ingestion of cyanidin-3-glucoside or a bilberry derived anthocyanin mix led to
a reduction in adenoma load in a dose dependent fashion. It should be noted that although
significant reductions in adenoma numbers were seen for cyanidin-3-glucoside (p< 0.001)
and Mirtoselect bilberry anthocyanins (p<0.05), the doses that were used were 0.3% of
the diet which is equivalent to 450 mg/kg/day or 2.6 g/80 kg human dosage, when the
authors extrapolated using the dose/surface area comparison between species [76].
When the Mirtoselect native bilberry mixture was extrapolated back to the amount of fresh
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berries that would need to be consumed, it was concluded that an individual would need
to consume ~740 g of fresh bilberry a day [75]. Given the large nature of the dose used in
the study, which is further complicated due to the presence of high sugar content (about
60% in blueberry), it is clear that one would need to lower the dose by identifying the active
principles in order to be a clinically-viable option.
Data from clinical trials
A limited number of clinical trials have been undertaken to assess the impact that
anthocyanins, taken in the form of either berry powder or as an anthocyanin-rich
standardized bilberry extract, has on colorectal cancer. The first study was a clinical trial
assessing whether an anthocyanin-rich standardized bilberry extract (Mirtocyan)
administered to patients (1.3, 2.8 or 5.6 g, containing 0.5-2.0 g anthocyanins) daily for 7
days before surgery would induce pharmacodynamics changes that would be in
agreement with chemopreventive efficacy [77]. Results from the study showed that a 7%
decrease in proliferation was observed in tumor tissues taken from patients when
compared to their pre-intervention values. Another clinical trial investigating the impact of
freeze-dried blackberry powder (60g/day, for 1 to 9 weeks) in colorectal cancer patients
showed beneficial changes in GM-CSF and IL-8, markers for proliferation and apoptosis
respectively [78].
A clinical trial assessing the impact of black raspberry (BRB) powder on biomarkers of
colorectal tumor development showed that the methylation patterns of three Wnt inhibitors
including WIF1, SFRP2, SFRP5 and the developmental regulator PAX6a were protectively
modulated in normal and in colorectal tumor tissues in patients receiving the black
raspberry powder (60 g/d) for an average of 4 weeks. Furthermore, the protective
modulation of methylation was associated with decreased expression of the enzyme that
transfers methyl groups to the cytosine nucleotides in genomic DNA, DNA (Cytosine-5-)18

Methyltransferase 1 (DNMT1) [79]. Interestingly, the authors also noted that black
raspberry powder decreased β-catenin as well as protectively modified Ki-67, TUNEL,
CD105, as well as DNMT1 in colorectal tissues from the 20 patients. CD105 and DNMT1
were also found to be modulated in adjacent normal tissues. The impact on β-catenin and
E-cadherin expression was also shown to be dose dependent, with the high dose (~ 4
weeks) BRB powder treatment yielding greater impact than the low dose (~ 2 weeks) BRB
powder treatment [79].
In addition to studies on colorectal cancer, anthocyanin-rich bilberry extract has also been
shown to reduce the amount of pro-inflammatory cytokines including TNF-α and IFN-γ in
colon biopsies from patients with ulcerative colitis (UC). Furthermore, serum levels from
UC patients that were successfully treated with anthocyanin-rich bilberry extract had
enhanced levels of immunoregulatory IL-10 and the Th-17 cell specific cytokine IL-22 and
reduced levels of TNF-α and IFN-γ [80]. In another clinical trial testing the impact of a
standardized anthocyanin-rich bilberry extract on UC disease activity showed that after 6
weeks of treatment, 63.4% of patients achieved remission and 90.9% of patients showed
a response. It was also noted that fecal calprotectin levels were also decreased during the
treatment, which further suggests that intestinal inflammation was reduced [81].
It should be noted that all of the anthocyanin-mediated colorectal cancer clinical trials
published to date have been conducted using anthocyanins rather than anthocyanidins.
Although the bioavailability of anthocyanins is very low in the plasma (<1%), greater
bioavailability has been found in colonic tissues [82]. This suggests that they may have
greater potential since they can directly interact with the colon tissue. Additionally, one
can posit that additional benefits in uptake, if administered in the aglycon form (ie as
anthocyanidins) or by utilizing a nano drug delivery vehicle such as bovine milk derived
exosomes (i.e. ExoAnthos).
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Exosomes
Size, history, sources
Exosomes are defined as membrane-bound vesicles that range in size from 30-100nm, in
diameter, feature a density in sucrose gradients of 1.13-1.19 g/ml, are highly enriched with
tetraspanin molecules and are of endocytic origin [83]. Exosomes were discovered in 1983
by Pan and Johnstone. In 1989, Pan and Johnstone named the vesicles exosomes [84].
Since their identification, exosomes have been isolated from essentially all biological fluids
such as saliva, peripheral blood, cerebrospinal fluid (CSF), urine, sweat, malignant
effusions and milk [85].
Exosome formation
Exosomes are initially formed via a process of endocytosis, with the internalization of the
cell membrane to yield endosomes (Figure 3). Following the formation of endosomes,
many small vesicles are formed inside the endosome by invagination of parts of the
endosomal, multi-vesicular body (MVB), membrane. The MVBs then fuse with the cell
membrane thereby releasing the intraluminal vesicles into the extracellular space.
Following their release, these vesicles are referred to as exosomes.
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Figure 3: Classic pathway of exosome formation. After endocytosis, endosomes are
formed via the internalization of the cell membrane (sidedness noted in the diagram as
blue for the initial internal face and black for the initial external face). A process of
invagination of the endosome yields smaller bodies inside the MVB, which can proceed to
processing via the golgi apparatus, be released via exocytosis yielding exosomes or be
degraded by the lysosome.
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Exosome composition
Exosomal membranes are primarily composed of lipids and proteins and are enriched with
lipid rafts [86]. The lipid composition of exosomes is distinctively rich in cholesterol,
ceramide, sphingomyelin, and phosphatidylserine[87]. However, exosomes contain
minimal to no lysobisphospatidic acid (LBPA), which distinguishes them from MVBs’
intraluminal vesicles (ILVs) [87]. Furthermore, the fatty acids in exosomes tend to be
saturated or monounsaturated, which in addition to the high concentration of cholesterol
is believed to lead to the lateral segregation of these lipids into exosomes during their
formation [88]. Results from proteomic studies suggest that exosomes contain specific
proteins from endosomes, plasma membrane, and cytosol [89]. Examples of proteins from
the endosome include Alix, Tsg101, Rab GTPase, SNAREs Annexin and Flotillin. Proteins
originally associated with the plasma membrane include tetraspanins, such as CD63,
CD81 and CD37. It should be noted that exosomes contain very few proteins from other
intracellular organelles such as the nucleus, mitochondria and Golgi [87].

Exosome cargo
In addition to proteins, exosomes have been found to carry as cargo within their lumen,
that include mRNA, miRNA, small noncoding RNA species such as structural RNAs, tRNA
fragments, vault RNA, small interfering RNAs, RNA transcripts that overlap with protein
coding regions and repeat sequences [88]. More recent data indicate the presence of
some DNA as well [90]. The RNA cargo contained within exosomes can either be taken
up by neighboring cells or transported by the circulating exosomes and taken up by distant
cells. Ultimately, the RNA cargo in exosomes is believed to function as a form of genetic
exchange between cells [86].
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Exosome role in cell to cell communication
Once called the “garbage bag” of cells, exosomes have been found to play an important
role in cell to cell communication. After finding that mRNAs and miRNAs were present in
exosomes derived from mast cells, it was also found that the mRNA in these exosomes
were transported to recipient cells and following uptake were translated into proteins thus
providing evidence for the ability of exosomes to transfer of genetic material [91]. It was
noted that not all mRNAs that were abundant in the secreting cells were packaged into
exosomes thereby suggesting that specific targeting machinery for mRNAs may exist [91].
It has also been shown that tumor derived exosomes can both suppress the function of
immune cells by promoting the differentiation of regulatory T lymphocytes or by inducing
apoptosis of activated cytotoxic T cells [92]. Exosomes can also induce immune
responses by transferring tumor antigens to dendritic cells and to present tumor antigens
[93]. Interestingly, it has been found that exosomes can fuse especially well with the
plasma membranes under acidic conditions mimicking those of the cancer cell
microenvironment [94].
Exosomes as therapeutics
Special interest in the application of exosomes for diagnostic as well as drug delivery
purposes has recently taken root within the scientific community. A key area of research
within our laboratory is in utilizing exosomes as a drug delivery vehicle. Prior to the work
conducted in this lab, the primary source of exosomes for drug delivery purposes was
from cell culture media and serum. In order to overcome the obvious limitations posed by
these sources such as quantity, safety, cost and translatability, our lab pioneered the use
of exosomes derived from bovine milk [95, 96]. Not only does bovine milk provide a
scalable source of exosomes, it also exhibits cross-species tolerance. Furthermore, no
adverse immune or inflammatory responses have been found [97].
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Exosomes derived from raw bovine milk can effectively deliver a variety of both hydrophilic
as well as lipophilic compounds such as curcumin, withaferin A (WFA), paclitaxel, celastrol
and doxorubicin. Moreover, tumor targeting of the exosomes with folic acid was shown to
increase biological efficacy. Exosomal formulations containing WFA, celastrol, or
curcumin have shown increased efficacy over drug alone in both in vitro and in vivo against
lung and breast cancer [95, 96]. Prior to the body of studies contained within this
manuscript no experiments were undertaken with colon cancer. In addition to the role of
the exosomes as a drug delivery vehicle, they are also believed to deliver an additional
“payload” of their own. For instance, our lab has identified the presence of immune-related
miRNAs such as miR-146a, -155, -181a and -223 in bovine milk derived exosomes [95].
The overarching goal of my Master’s work has been to investigate the use of bilberry
derived Anthos as both a chemotherapeutic as well as chemopreventive agent in
colorectal cancer as well as FAP. I have also undertaken preliminary studies with
ExoAnthos, with the ultimate goal of utilizing this nano-delivery system in future work.
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METHODS & MATERIALS
Anthocyanins and anthocyanidins
The individual anthocyanins, delphinidin 3,5-diglucoside, malvidin 3,5-diglucoside,
petunidin 3,5-diglucoside and cyanidin 3-monoglucoside were a kind gift from Dr. Inder P.
Singh of the National Institute of Pharmaceutical Education and Research (S. A. S. Nagar,
India). The individual Anthos, delphindin, cyanidin, petunidin, malvidin, peonidin and
pelargonidin, were purchased from Chromadex (Irvine, CA). The native Anthos mixture
isolated from bilberry with purity of >80% was generously provided by 3P Biotechnologies,
Inc. (Louisville, KY).
Isolation of bilberry-derived Anthos
The native Anthos mixture from bilberry obtained from 3P Biotechnologies (Louisville, KY)
were further enriched using C18 Sep-Pak cartridges (Waters, Milford, MA, USA). Anthos
were eluted with acidified (0.1% HCl) ethanol. The enriched extract was then dried using
a Savant Speed-Vac (Thermo Scientific, USA) and stored at -20 °C. Purity was verified
using HPLC-PDA-UV. Briefly, 15 µl samples were analyzed using a Shimadzu Premier
C18 reverse-phase column (250x4.6 mm i.d., 5 µm). Mobile phase A was composed of
water: formic acid: acetonitrile (87:10:3) and mobile phase B was composed of water:
formic acid: acetonitrile (40:10:50). The flow rate was 0.6 ml/min and the gradient condition
was 0-5 min 5% B; 5-15 min 15% B; 15-20 min 25% B; 20-30 min 35% B; 30-40 min 45%
B; 40-45 min 100% B; 45-50 min 5% B. Anthos were detected at 520 nm by PDA-UV and
total Anthos concentration was calculated using a standard curve. The reference
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compounds were purchased from Chromadex (Irvine, CA) and Cayman Chemical
Company (Ann Arbor, MI).
Isolation of milk-derived exosomes
Exosomes were isolated from raw bovine milk using differential centrifugation using the
method described by Munagala et al., [95] Briefly, in order to remove casein aggregates,
fat globules as well as other debris, the milk was first centrifuged at 20,000xg for 30
minutes at 4 ºC using a TA-10259 rotor and Allegra 25R centrifuge (Beckman Coulter,
Fullerton, CA). The resulting whey was then filtered by passing through grade 90
cheesecloth. In order to remove microvesicles and large particles, the whey was then
subsequently centrifuged at 100,000xg for 60 minutes at 4 ºC using an Optima LE-80K
Ultracentrifuge (Beckman Coulter, Fullerton, CA). About two thirds of the resulting
supernatant was then carefully transferred to new tubes, discarding the bottom one third
of the supernatant and the pellet, and further centrifuged at 135,000xg for 90 minutes at
4 ºC using an Optima LE-80K Ultracentrifuge (Beckman Coulter, Fullerton, CA). After
discarding the supernatant, the resulting exosome pellet was washed three times with
PBS. The pellets were pooled and suspended in PBS (final protein content adjusted to 6
mg/ml) using a Potter homogenizer. The homogenized suspensions were then filtered
through a 0.22 µm filter for sterilization. Exosomal preparations were then assessed for
size distribution, morphology, and protein markers using Zetasizer (Malvern Instruments
Ltd., Malvern, Worchestshire, UK), atomic force microscopy (Oxford Instruments, Goleta,
CA) and Western blot, respectively. Bovine colostrum-derived exosomes, prepared the
same as the milk exosomes, were provided for the studies as a kind gift from 3P
Biotechnologies (Louisville, KY).
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Protein determination
Protein estimation for exosomal preparations was assessed using a bicinchoninic acid
(BCA) assay (Thermo Scientific, Rockford, IL). In order to determine protein concentration,
diluted exosomal preparations were compared, in triplicate, to a serially-diluted bovine
serum albumin (BSA) standard curve.
Loading of the Anthos onto the exosomes (ExoAnthos)
The native mixture of bilberry Anthos was loaded onto exosomes by mixing Anthos
(dissolved in ethanol and water) with the exosomes in a 1:5 (Anthos:Exosomal protein)
ratio at room temperature (22 ºC). Unbound Anthos and any protein coagulates were
removed using low speed centrifugation (10,000×g for 10 min), and the exosomes that
were loaded with Anthos were then collected by ultracentrifugation (135,000 x g for 1.5 h).
The pellet was then suspended in PBS and passed through a 0.22 µm filter and stored at
-80 ºC.
Analysis of drug loading
In order to determine the practical drug load of Anthos in the ExoAnthos formulation, the
protein and Anthos concentrations were measured. Briefly, a 50 µl aliquot of ExoAnthos
formulation was mixed with 950 µl of acidified ethanol (0.1% HCl). The precipitated
proteins were separated by centrifugation (10,000 x g for 10 minutes). The Anthos
contained in the supernatant was then analyzed using a SpectraMax M2 spectrometer
(Molecular Devices, Sunnyvale, CA). Anthos were detected at 520 nm and total Anthos
concentration was calculated using a standard curve. Reference Anthos were acquired
from Chromadex (Irvine, CA). Anthos concentrations were confirmed via HPLC-PDA. The
pelleted exosomal proteins were determined by the BCA method described above. The
percent drug load when then calculated by dividing the amount of Anthos by exosomal
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proteins x 100 [95]. The proportionate loading of individual Anthos was confirmed using
HPLC-DAD.
Characterization of Exosomes and ExoAnthos
The size of control colostrum exosomes and ExoAnthos, which were diluted in PBS to 1
mg/ml, were determined using a Zetasizer (Malvern Instruments Ltd, Malvern,
Worcestershire, UK). Morphology of the exosomes and ExoAnthos was determined by
atomic force microscopy (AFM). Briefly, exosomes and ExoAnthos were diluted with
deionized water to 10 µg/ml. A 2 µl aliquot of each sample was then placed on a silica
wafer and air dried for 30 min. Images were captured using an Asylum MF-3D AFM
(Oxford Instruments, Goleta, CA) in tapping mode using aluminum-coated silicon probes.
The amplitude, topographic height and phase retraces were imaged with a fixed force
(<1nN) at a scanning rate of 1 Hz. Images were processed using IGOR software.

Cells, culture conditions and treatments
The APC wild-type HCT 116 (ATCC® CCL-247™) and APC mutant Caco-2 (ATCC® HTB37™) colon cancer cell lines were acquired from American Type Culture Collection
(Manassas, VA, USA). The APC mutant colon cancer cell line HT-29 (ATCC® HTB38D™) was a kind gift from Dr. Nobuyuki Matoba (University of Louisville). HCT-116 and
HT-29 cells were maintained in McCoy’s 5A medium (Gibco, Grand Island, NY)
supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin in a
humidified atmosphere containing 5% CO2 at 37 °C. Caco-2 and CCD-18Co cells were
maintained in Memα (Gibco, Grand Island, NY) supplemented with 20% FBS, 100 U/ml
penicillin and 100 ug/ml streptomycin in a humidified atmosphere containing 5% CO 2 at
37 °C.
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Measurement of cell viability
The cytotoxicity of the colostrum exosomes, the bilberry Anthos and ExoAnthos in colon
cancer cell lines was assessed by enzymatic reduction of the tetrazolium dye MTT. Briefly,
3.0 x103 cells/well were grown in a 96-well tissue culture plates and were then exposed to
varying concentrations of the Anthos, ExoAnthos, the exosomes or vehicle control 24
hours after seeding. After 72 h treatment, cells were incubated with 5 mg/ml MTT reagent
for 2 h. The resulting formazan crystals were then solubilized in DMSO and
spectrophotometrically measured at 570 nm (Bio-rad, Philadelphia, PA, USA). IC50 values
were then determined using Calcysyn software version 2.1 (Biosoft, Cambridge, England).

Western-blot analysis
For western-blot analysis, 50 µg of protein was resolved using gel electrophoresis and
electrotransferred to polyvinylidene difluoride membranes by semi-dry transfer (Biorad
Trans-blot SD, Hercules, CA). Blots were blocked with 4% dry powder milk or BSA for 1 h
and then incubated with primary antibodies at 4ºC overnight and secondary antibodies
conjugated to peroxidase for 1 h at room temperature. Blots were then developed with an
ECL detection system. Densitometric analysis was then performed using ImageJ 1.x
software [98].

Animal model for FAP and CRC
ApcMin/+ mice are often used to study FAP and CRC. The mice exhibit a germline nonsense
mutation at codon 850 of the APC gene, which causes the spontaneous development of
polyps predominantly in the small intestine by the age of 10-12 weeks.
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ETBF
Enterotoxigenic Bacteriodes fragilis (ETBF) has been found to exist asymptomatically in
12.4% of individuals and in 27% of individuals with diarrhea symptoms [99]. It is well known
as a global cause of diarrheal disease that is accompanied by colitis in both humans and
animals. The pathogenicity associated with ETBF is due to the secretion of a 20 kDa zincdependent metalloprotease toxin, B. fragilis toxin (BFT), which binds to colonic epithelial
cells and leads to the cleavage of E-cadherin, which is a tumor suppressor protein and
the secretion of interleukin-8 [100]. This ultimately leads to the stimulation of proliferation
and migration of human colon cancer cells [101]. Furthermore, BFT has also been shown
to induce pro-inflammatory cytokine secretion by further activating the NFƘB pathway
[101].

In vivo CRC studies
Animal experiments were performed in agreement with an approved protocol by the
Institutional Animal Care and Use Committee at the University of Louisville. Breeding
colonies were established by Dr. Nejat K. Egilmez’s lab [102] at the University of Louisville
using C57BL/6J Min/+ (ApcMin/+) mice which were originally attained from Jackson
Laboratories (Bar Harbour, ME, USA). Mice were genotyped for the APC mutation using
PCR according to the protocol outlined by Jackson Laboratories. Mice were fed a standard
chow diet and received water ad libitum for the duration of the study and were maintained
on a standard light/dark cycle. At 5-6 weeks age, animals were administered antibiotic and
4 days later they were administered ETBF to promote tumorigenesis. One week following
ETBF inoculation, animals began their respective treatment regimen. Two studies were
performed to test the impact of the Anthos on tumor number. In the first study male ApcMin/+
mice were orally administered (by gavage) 20 mg/kg Anthos or vehicle control. Animals
were treated 5 times a week for 4 weeks. Animals were euthanized in the fed state at 12
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weeks and colon tumors were counted. For the second study female ApcMin/+ mice were
orally administered (by gavage) 40 mg/kg Anthos or vehicle control. Animals were treated
3 times a week for 4 weeks. Animals were euthanized in the fed state at 11-12 weeks and
colon tumors were counted.

In vivo FAP study
Animal experiments were performed in agreement with an approved protocol by the
Institutional Animal Care and Use Committee at the University of Louisville. Breeding
colonies were established by Dr. Nejat K. Egilmez’s lab [102, 103] at the University of
Louisville using C57BL/6J Min/+ (ApcMin/+) mice which were originally attained from
Jackson Laboratories (Bar Harbour, ME, USA). Mice were genotyped for the APC
mutation using PCR according to the protocol outlined by Jackson Laboratories. Mice
were fed a standard chow diet and received water ad libitum for the duration of the study
and were maintained on a standard light/dark cycle. Treatments began when animals were
8-9 weeks old. Male (n=4) and female (n=4) ApcMin/+ mice were orally administered (by
gavage) 40 mg/kg Anthos or vehicle control. Animals were treated 3 times per week for 5
weeks. Animals were euthanized at 13-14 weeks. Following fixation of intestines using
formalin, intestinal polyps were counted using a microscope (Leica EZ4, Wetzlar,
Germany) by four different experienced individuals after blinding the samples.

Data analysis
Statistical analysis was performed using Graph Pad Prism statistical software version 4.03
(La Jolla, CA). Student’s t-test was used for both animal studies. IC50 values were
determined using CalcuSyn software version 2.1 (Biosoft, Cambridge, England).
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RESULTS
Purity of bilberry-derived Anthos
Prior to performing any experiments with the Anthos, we first determined the purity of each
Anthos preparation. HPLC-DAD analysis yielded a chromatogram (Figure 4) with five
peaks featuring retention times that matched in retention times with the reference Anthos,
delphinidin, cyanidin, petunidin, peonidin, and malvidin. The bilberry Anthos mixture used
in these experiments were confirmed to have a purity greater than 96% and an average
purity of 98%.
Anti-proliferative effects of anthocyanins versus Anthos on colon cancer cells
In order to determine whether a difference exists between the activities of Anthos versus
anthocyanins (delphinidin, cyanidin, delphinidin 3,5-diglucoside, cyanidin 3-glucoside, and
cyanidin 3,5-diglucoside) in colon cancer cells, we compared the anti-proliferative activity
of two individual Anthos, delphinidin and cyanidin, with their respective anthocyanins, in
HCT-116 colon cancer cells. As shown in Figure 5, a clear benefit is derived from the
cleavage of the sugar moiety from the anthocyanin component. The greatest advantage
in the reduction of IC50 is shown for delphinidin which yielded a greater than 6-fold
reduction when the sugar moiety was absent. A similar although slightly lower reduction
was observed for cyanidin versus cyanidin 3-glucoside, and cyanidin 3,5-diglucoside, with
2- and nearly 5-fold reductions, respectively. The difference in the anti-proliferative
activities for the Anthos versus their respective anthocyanins is most likely due to the
differences in size and partition coefficient associated with the possession of the sugar
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moiety presumably affecting their cell uptake. Furthermore, it should be noted that little
difference was observed for mono versus di-glycosylated forms of cyanidin. Ultimately,
the absence of the sugar moiety enables anthocyanidins to be passively absorbed by the
gut epithelial cells [61].
Anti-proliferative effects of Anthos on colon cancer cells
After confirming that Anthos yielded greater antiproliferative properties than anthocyanins
we next set out to determine the relative anti-proliferative activity of the individual Anthos
in colon cancer cells. We then measured antiproliferative activity for the available four
Anthos, delphinidin, petunidin, malvidin, cyanidin and compared them with the native
bilberry Anthos mixture in HCT-116 and HT-29 colon cancer cells. As shown in Figure 6
and Table 1 the lowest IC50 was achieved by delphinidin (23 µM), followed by petunidin,
malvidin, and cyanidin in HCT-116 cells. A slightly different trend was observed for HT-29
cells with delphinidin and petunidin yielding the lowest IC50 value of 68 µM followed by
cyanidin and malvidin. Overall, it was noted that the HCT-116 was more sensitive than
the HT-29 cells to all the Anthos tested.
In vitro toxicity study with Anthos in normal colon cells
Prior to testing Anthos in an in vivo model, we first assessed if Anthos presented any
toxicity to normal colon CCD-18Co cells. Comparison of the selectivity index values
calculated by comparing Anthos treated CCD-18Co normal colon cells with HT-29 and
HCT-116 colon cancer cells yielded values of 9 and 14 for HT-29 and HCT-116 colon
cancer cells, respectively (Figure 7). These values were well above the recommended
minimal SI value of 3 that is used to determine whether a drug selectively targets cancer
cells over normal cells. Therefore, given the in vitro selectivity results we decided that
Anthos were selective toward cancer cells and were would be promising to test against
FAP and CRC mouse models.
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Figure 4 Representative chromatogram of C18 enriched bilberry-derived Anthos: HPLC profile of
native mixture of bilberry-derived anthocyanidins including delphinidin (Dp), cyanidin (Cy),
petunidin (Pt), peonidin (Pe), and malvidin (Mv). The purity was verified to be greater than 96%
for all Anthos samples used in the studies included in this thesis.
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Figure 5 Antiproliferative activity of individual anthocyanidins and their anthocyanin
counterparts against colon cancer cell line HCT-116: Colon cancer cell line HCT 116 was treated
with various concentrations of the individual anthocyanidins cyanidin (Cy) or delphinidin (Dp) and
their anthocyanin counterparts cyanidin 3-glucoside (C3G), cyanidin 3,5-diglucoside (C3DG) or
delphinidin 3,5-diglucoside (D3DG) respectively for 72 h and the effect on cell growth inhibition
was assessed using an MTT assay. Data represent average ±SD (n=3).
35

HCT116

% Cell Survival

100
80
60
40
20
0
0

50

100
Anthos [µM]

150

200

150

200

HT-29

% Cell Survival

100
80
60

40
20
0
0

50

100

Anthos [µM]
Figure 6 Antiproliferative activity of individual anthocyanidins against colon cancer cell lines:
Colon cancer cell lines HCT116 and HT-29 were treated with various concentrations of individual
anthocyanidins including cyanidin (Cy), delphinidin (Dp), malvidin (Mv) and petunidin (Pt) for 72
h and the effect on cell growth inhibition was assessed using an MTT assay. Data represent
average ±SEM (n=3-4).
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Cell line
Dp
Cy
Pt
Mv

HCT116 IC50
[µM]
23
84
53
66

HT-29 IC50
[µM]
68
103
68
156

TABLE 1: Antiproliferative activity of individual anthocyanidins against colon cancer cells.
Values listed for the four anthocyanidins tested including cyanidin (Cy), delphinidin (Dp),
malvidin (Mv) and petunidin (Pt).
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Figure 7 Antiproliferative activity of native bilberry Anthos mixture against colon normal cells
and cancer cell lines: Colon normal cells CCD-18Co and colon cancer cell lines HCT-116 and HT-29
were treated with various concentrations of bilberry-derived Anthos for 72 h and the effect on
cell growth inhibition was assessed using an MTT assay. Data represent average ±SEM (n=4).
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Impact of Anthos treatment on polyp development in ApcMin/+ mice FAP model
In order to determine if Anthos treatment beneficially impacts intestinal polyp number in
vivo, ApcMin/+ mice were treated with 40 mg/kg Anthos three times per week for four weeks
by oral gavage. Both male and female mice (n=4 per group) were tested. Results from the
study (Figure 8) showed that intestinal polyp number was significantly reduced in both
male and female mice treated with the Anthos (p=0.02 and p=0.004, respectively). The
average number of polyps for vehicle control animals was 41 polyps and with Anthos
treatment it was 18 polyps. A slightly higher number of polyps was found in the female
mice but reduction in the polyps with the Anthos treatment was evident, in fact, the effect
was more pronounced (3.1 fold reduction, p=0.004) compared to male mice (1.8 fold
reduction, p=0.02).
Impact of Anthos treatment on colon tumor development in ETBF ApcMin/+ mice
CRC model
Upon completion of in vitro testing of Anthos in both APC wild-type and APC mutant cell
lines, the next step was to investigate whether Anthos treatment would impact colon tumor
number in vivo in ApcMin/+ mice which were treated with Anthos at either 20 mg/kg Anthos
5 times per week or 40 mg/kg 3 times per week for 4 weeks by oral gavage. Results from
the study (Figure 9) showed a significant reduction in the number of colon tumors with the
Anthos treatment compared with the vehicle treatment (p=0.03). The average number of
tumors was reduced from 23 in control mice to 9 in Anthos-treated mice. Furthermore,
similar average tumor counts were noted in both male and female animals (p<0.05). These
results support our in vitro findings.
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Figure 8 Antipolyp activity of bilberry-derived Anthos against intestinal polyps: ApcMin/+ mice
were treated via oral gavage with bilberry derived Anthos three times a week (40 mg/kg bw) or
vehicle control. Data represent the distribution of animal polyp counts by gender, with the
average noted. Male Anthos vs. control p=0.02 and female Anthos vs. control p=0.004.
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Figure 9 Anti-tumor activity of bilberry-derived Anthos against colon tumors: ApcMin/+ mice
were treated via oral gavage with bilberry derived Anthos three times per week (40 mg/kg bw),
five times per week (20 mg/kg bw), or vehicle control. Data represent the distribution of animal
tumor counts by gender, with the average noted. Male and female Anthos vs. control p<0.05.
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Preliminary work investigating role of Anthos in the potential inhibition of EGFR
and Src
We next probed the mechanism of Anthos by western-blot analysis. Preliminary results
comparing the phosphorylation of EGFR by probing for the phosphorylation of tyrosine
1048 (Y1048), to total EGFR, corrected for loading using β-actin suggest that Anthos led
to a dose-dependent decrease in EGFR phosphorylation (Figure 10). A more pronounced
decrease in phosphorylation was observed for Src at tyrosine 416 (Y416) (Figure 11).
Minimal to no changes were seen in the expression of either total EGFR or total Src
following Anthos treatment. These association studies will be used as the foundation for
my mechanistic work which will be further elucidated with additional work to be completed
in the near future.
Loading and characterization of exosomes and ExoAnthos
We investigated if a nano-formulation of Anthos would improve its potency. We chose the
milk-derived exosomal nano formulation for Anthos (ExoAnthos) because of higher Anthos
loading compared with the milk exosomes. An average practical drug loading of 25% was
achieved for ExoAnthos. The average size for exosomes and ExoAnthos measured by
the Zetasizer was 81 nm (Figure 12). Moreover, the surface morphology of ExoAnthos,
determined by AFM, showed that ExoAnthos maintained the same characteristic spherical
shape as the original exosomes.
Profile of Anthos loading onto/into colostrum derived exosomes
We next wanted to confirm that each of the five anthocyanidins, delphinidin, cyanidin,
petunidin, peonidin, and malvidin present in the mixture were loaded proportionately
onto/into the exosomes. We also wanted to confirm that the Anthos ratio was maintained
during the storage. The HPLC profiles of the five Anthos contained in the free Anthos
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mixture (Figure 13) remained nearly the same as the native bilberry Anthos ratio for
ExoAnthos on both day 0 and day 12 (Figure 13). Therefore, not only do the individual
moieties of the Anthos mixture load equally, the ExoAnthos formulation was stable
following freezing and thawing.
Anti-proliferative effects of Exosomes alone on colon cancer cells
Prior to assessing the impact of ExoAnthos, we first determined whether the exosomes
per se (in the absence of Anthos) possessed anti-proliferative activity in the colon cancer
cell lines, HCT-116 and HT-29 or normal CCD-18Co colon cells. Treatment of these colon
cancer cell lines and normal cells with 0-200 µg/ml of exosomal proteins for 72 h resulted
in minimal to modest cell growth inhibition (Figure 14). The APC wild-type cells, HCT-116
showed a maximum level of inhibition of 36% whereas normal CCD-18Co cells and the
APC mutant cell line HT-29 showed only a slight cell kill (0 to 10%). These results suggest
that colostrum exosomes possess no in vitro toxicity to the normal cells and that they
possess an intrinsic activity against colon cancer cells specifically. This “internal payload”
effect is an exciting feature that our lab has also identified for other cancers such as breast
and lung cancers [104].
Anti-proliferative effects of bilberry Anthos versus ExoAnthos in normal colon and
colon cancer cell lines
We next compared the impact of exosomal formulation of the Anthos on the proliferation
of the colon cancer cell lines HT-29, HCT-116, Caco2 and normal CCD-18Co colon cells.
The results from these studies (Figure 15) showed a clear
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Figure 10 Changes in EGFR phosphorylation after treatment with Bilberry derived Anthos: Colon
cancer cell line HT-29 was treated with various concentrations of bilberry-derived Anthos
overnight and the effect on phosphorylation of EGFR at Y1068 was assessed using western blot
analysis and compared to total EGFR and β-actin loading control.
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Figure 11 Changes in Src phosphorylation after treatment with Bilberry derived Anthos: Colon
cancer cell line HT-29 was treated with various concentrations of bilberry-derived Anthos
overnight and the effect on phosphorylation of Src at Y416 was assessed using western blot
analysis and compared to total Src and β-actin loading control.
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Figure 12 Morphology and size of milk exosomes and ExoAnthos: Exosomes derived from bovine
milk and ExoAnthos were analyzed by AFM (A) and zetasizer (B). Amplitude and topographic
images were captured simultaneously using a fixed force <1 nM and scanning rate of 1 Hz.
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0 and 12 days after loading compared to Anthos reference.
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Figure 14 Antiproliferative activity of Exosomes against colon normal cells and cancer cell lines:
Colon normal cells CCD-18Co and colon cancer cell lines HCT-116 and HT-29 were treated with
various concentrations of milk derived exosomes for 72 h and the effect on cell growth inhibition
was assessed using an MTT assay. Data represent average ±SEM (n=3).
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Figure 15 Antiproliferative activity of Anthos vs. ExoAnthos against colon normal cells and
cancer cell lines: Colon normal cells CCD-18Co and colon cancer cell lines HCT-116, HT-29 and
Caco2 were treated with various concentrations of bilberry-derived Anthos and ExoAnthos for 72
h and the effect on cell growth inhibition was assessed using an MTT assay. Data represent
average ±SEM (n=3).
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Cell line

IC50 Anthos
(µM)

CCD-18Co
HCT116
HT-29

1050
75
124

SI Anthos

IC50 ExoAnthos
(µM)

SI ExoAnthos

14
9

407
20
8

20
51

Fold
difference in
IC50 values
4
16

TABLE 2: Antiproliferative activity and selectivity index for bilberry derived Anthos and
ExoAnthos against colon cancer and normal colon cells
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increase in the anti-proliferative properties of Anthos against colon cancer cells, with 416-fold decreases in the IC50 values of ExoAnthos as compared to the free Anthos (Table
2). One can posit that the improved anti-proliferative effects of the ExoAnthos formulation
over Anthos alone is most likely due to the increased cell uptake and stability in media of
the ExoAnthos over Anthos. Part of the higher potency of ExoAnthos may be attributed to
the intrinsic effect of the exosomes alone.
In order to determine whether Anthos or ExoAnthos were selective toward colon cancer
over normal colon cells in vitro, we determined the selectivity index (SI) values for both
HCT 116 and HT-29 colon cancer cells compared to normal colon CCD-18Co cells. The
results (Table 2) showed not only that both Anthos and ExoAnthos were selective for colon
cancer over normal colon cells, but that ExoAnthos enhanced this selectivity, with the
greatest increase yielded in HT-29 cells which went from an SI value of 9 for Anthos to 51
for ExoAnthos. Overall, these results confirm that Anthos and ExoAnthos do not show in
vitro toxicity for the normal CCD-18Co colon cells and that the cytotoxicity is specific for
colon cancer cells.

Impact of Milk-derived ExoAnthos vs. Colostrum-derived ExoAnthos on the Antiproliferative effects in colon cancer cells
The next generation of exosomes that 3P Biotechnologies has been developing are
derived from bovine colostrum. Prior to this work, no in vitro or in vivo data had been
collected comparing the milk exosomes loaded with Anthos versus the colostrum
exosomes loaded with Anthos. To compare the two formulations, we assessed the antiproliferative activity of the milk- and the colostrum-derived ExoAnthos formulations
alongside the free Anthos in the colon cancer cell line HCT-116. The results from these
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studies (Figure 16) confirmed that no difference in the anti-proliferative properties exists
between colostrum ExoAnthos and milk ExoAnthos formulations for HCT-116 colon
cancer cells. Both formulations showed a clear increase in the anti-proliferative properties
of ExoAnthos over the free Anthos against colon cancer cells. With 4-fold decreases in
the IC50 values of Anthos, when delivered by either colostrum- or milk-derived exosomes.
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Figure 16 Antiproliferative activity of Anthos vs. Milk ExoAnthos and Colostrum ExoAnthos
against colon cancer cell line HCT-116: Colon cancer cell line HCT116 was treated with various
concentrations of bilberry-derived Anthos, milk ExoAnthos and colostrum ExoAnthos for 72 h and
the effect on cell growth inhibition was assessed using an MTT assay.
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DISCUSSION
Although great progress has been made in the treatment of CRC, it still remains the third
leading cause of cancer related death. Additionally, FAP remains an orphan disease with
the only approved treatment being surgical resection of the colon. Furthermore, even after
surgical resection, individuals with FAP still face the risk of developing cancers of the small
intestine. Therefore, there is an urgent need for developing novel treatments to combat
both CRC as well as FAP.
The plant pigments known as anthocyanins have been consumed by humans throughout
history. Within recent history anthocyanins have become an area of interest for their
potential benefits to human health. Although benefits have been noted for anthocyanins,
limitations have also become apparent due to their limited bioavailability and stability.
Previous work from our lab has shown that Anthos are more potent than anthocyanins in
inhibiting non-small-cell lung cancer cell growth [58, 96]. Additionally, work from our lab
also has shown that both dietary black raspberry and blueberry caused significant
inhibition of breast cancer in a rat model [105] and lung cancer in a mouse model [106].
However, prior to these studies no work had been conducted to test the impact of Anthos
on CRC or FAP. Therefore, for my Master’s project, after working on Anthos and
ExoAnthos in breast cancer initially, I have focused my research to investigate the impact
of Anthos and ExoAnthos on colorectal cancer and FAP, the results of which are contained
within this thesis.
Previous studies in our lab have shown that differences exist in the antiproliferative
capacity of Anthos versus anthocyanins in lung cancer [96]. Results from the comparison
54

of Anthos with their respective anthocyanins show that delphinidin, and cyanidin are more
potent that their 3-monoglucoside and 3,5-diglucoside anthocyanin counterparts in the
colon cancer cell line HCT-116. These results are not surprising considering that Anthos
not only are somewhat more lipophilic due to their higher partition coefficients than their
anthocyanin counterparts and are therefore able to be taken up passively by cells whereas
anthocyanins are known to require active transport.
Interestingly, when the colon cancer cell lines, HCT-116 and HT-29 were treated with
individual Anthos, including delphinidin, cyanidin, malvidin, or petunidin, different levels of
antiproliferative properties were noted for each compound. Furthermore, although
delphinidin and petunidin yielded the lowest IC50 values, slightly different trends were
noted for the remaining Anthos in each cell line. Moreover, slightly lower IC50 values were
achieved by HCT-116 cells when compared to HT-29 cells. Structure-function relationship
differences have been suggested to exist previously. For instance, it was noted that
delphinidin and cyanidin inhibited LPS-induced COX-2 expression, whereas malvidin,
peonidin and pelargonidin did not show a similar trend [107]. Additionally, different Anthos
substitution patterns were found to lead to different cellular signaling cascades effects
[108]. For instance, only malvidin which features methoxy groups at the 3’ and 5’ positions
of the B-ring lead to inhibition of cAMP-specific phosphodiesterases (PDEs) whereas,
cyanidin and delphinidin were shown to inhibit EGFR in human vulva carcinoma A431
cells [108]. However, it should be noted that the authors of this study did not investigate
petunidin, which showed the second highest antiproliferative impact, after delphinidin, in
our studies with HT-29 and HCT-116 colon cancer cells. Therefore, more work is still
needed to uncover differences in mechanisms, which may exist between individual Anthos
and whether alternative mixtures may provide an additional synergistic value over the
native bilberry mixture.
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In addition to the trends noted for the individual Anthos, HCT-116 cells also appeared to
be more sensitive to the native mixture of the Anthos from bilberries when compared to
HT-29 cells. This difference between the two cell lines is perhaps due to the influence of
Anthos on p53, which is active in HCT-116 but mutated in HT-29 cells. It has been
previously reported that anthocyanins alter the expression of p53 [109]. Given the
preliminary findings showing decreased activity of EGFR and Src one could postulate that
this could lead to decreased STAT3 activity thereby resulting in changes in the expression
of factors such as p53 along with a host of other key players in carcinogenesis such as cMyc, Bcl-2, Bcl-xL, survivin, Cyclin D1 among many others [110-114]. This is due to the
ability of STAT3 to act both directly and indirectly due to its ability to mediate the
expression of or physically associate with other transcription factors thereby suppressing
or enhancing gene regulatory functions [115]. Additional mechanistic studies are planned
to clearly elucidate the specifics of the pathway(s). We also plan to examine the effects of
the individual Anthos and the optimized Anthos mixture for their relative effects on the
EGFR and Src activities.
Individuals with FAP characteristically develop hundreds to thousands of polyps in their
intestines. Typically by their late teens to early twenties, FAP patients undergo CRC
prophylactic surgery. Given the lack of treatment options for FAP, developing alternative
preventative treatment options clearly represents an “unmet” need. With this in mind, the
potential application of Anthos to the prevention of FAP is a key possibility following the
successful in vitro results with the colon cancer cell lines HT-29, HCT-116 and Caco-2. In
vivo studies assessing the impact that Anthos has on FAP in ApcMin/+ mouse model
showed significant decreases in intestinal polyp number in the Anthos-treated mice
compared to vehicle treatment in both male and females (p=0.02 and p=0.004
respectively). Interestingly, it was previously shown that APC deficiency was associated
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with an increase in EGFR activity and c-Src expression in ApcMin/+ mouse adenomas and
intestinal enterocytes [116]. In light of the preliminary in vitro findings with Anthos
decreasing the activity of EGFR and c-Src, we postulate that Anthos is decreasing polyp
formation via this pathway. Further studies will be undertaken to better study the true
nature of the relationship between Anthos and receptor and non-receptor tyrosine kinases
using the ApcMin/+ model for FAP. Therefore, given the significant decrease in polyps
observed and the mechanistic implications, the potential for Anthos treatment for FAP
patients appears promising.
In addition to the promising results attained with the chemoprevention and FAP study in
the ApcMin/+ mouse model, additional in vivo work assessing the impact of Anthos on a
CRC ApcMin/+ ETBF mouse model showed that Anthos treatment significantly (p<0.05)
lowered the number of colorectal tumors in the Anthos-treated mice compared to vehicle
treatment. These results corroborate with the in vitro data. ETBF, a subtype of B. fragilis
that secrets the metalloprotease enterotoxin B. Fragilis toxin (BFT), is associated with
diarrheal disease in both humans and animals as well as active inflammatory bowel
disease. A study looking at the prevalence of ETBF found that 26.8% of individuals with
diarrhea and 12.4% of individuals without diarrhea had stool samples that were positive
for the presence of ETBF [99]. In addition to increasing the secretion of chloride and
permeability of intestinal epithelial cells, BFT also activates STAT3 and TH17 responses
and leads to increased Cox-2. Given the preliminary in vitro data which suggests that
Anthos decreases the activity of EGFR and Src, one could posit that Anthos treatment
may act by effectively decreasing the activity of STAT3 and ultimately altering downstream
expression of Cox-2, c-myc etc. Additional in vitro and in vivo studies will be conducted to
further elucidate this pathway. Overall, results from in vivo work with an ApcMin/+ mouse
model for FAP offer an exciting possibility for potential treatments in the future.
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Benefits of exosomal delivery have been established within our lab for drugs such as
withaferin A, celestrol and paclitaxel in lung cancer [96, 97]. One of the key goals of my
graduate research project is to utilize exosomal delivery for Anthos. The average drug
load attained for the ExoAnthos is 25%. Using HPLC-PDA-UV it has also been found that
all the individual Anthos were loaded proportionately. Furthermore, loading of the Anthos
onto/into the exosomes did not significantly change their size or morphology. When
comparing the impact that exosomal delivery of the Anthos has on colon cancer cell
proliferation using the APC mutant and APC wild-type colon cancer cell lines, 16-fold and
4-fold reductions in the IC50 values were found in the respective HT-29 and HCT-116 cells.
These results correspond with our previous findings for other drugs delivered using
exosomes [104]. Therefore, the results support our initial hypothesis that exosomal
delivery will improve Anthos potency presumably due to increased bioavailability and
stability of Anthos.
Bovine milk-derived exosomes have been well established as a nano drug carrier within
the Gupta lab [95, 96]. Before switching from bovine milk to bovine colostrum derived
exosomes within the study, the new system was investigated and compared to Anthosloaded milk exosomes. Results from the comparison of milk- versus colostrum-derived
exosomes loaded with Anthos showed that the colostrum exosomes resulted in higher
Anthos loading, although no significant differences were found in the anti-proliferative
activity of the two formulations. Therefore, once this was established, my future work will
utilize the colostrum-derived exosomes.
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SUMMARY & CONCLUSIONS
The findings from these series of studies establish the therapeutic potential of Anthos on
both CRC and FAP. In addition to confirming previous findings by our lab that Anthos are
more potent than anthocyanins, the results from in vitro work testing of the individual
Anthos also illustrate the different potencies of specific Anthos such as delphinidin and
petunidin over malvidin and peonidin. Our findings from the in vitro studies also suggest
that great promise exists for ExoAnthos in further enhancing Anthos effects. Preliminary
mechanistic work suggested that Anthos resulted in dose-dependent decrease in the
phosphorylation of Src (Y418) and EGFR (Y1068) which could potentially serve as one of
the pathways by which Anthos may be decreasing cell proliferation.
Current limitations of this work include the lack of an in vivo dose-escalation study.
Additionally, further studies need to be completed to more definitively elucidate the nature
of the interaction between Anthos, EGFR, and Src and the downstream targets such as
pSTAT5b, total pSTAT5b, pSTAT3, total STAT3, Cox-2, c-myc, Cyclin D1 and D2, βcatenin et cetera. Future work will also focus on identifying an optimal mixture of Anthos,
followed by the generation of an exosomal formulation featuring this specific mixture. One
of the key limitations of using the ExoAnthos formulation is with low drug load. Therefore,
future work will also investigate the kinetic parameters to increase the Anthos loading
onto/into the exosomes. An additional area that will be investigated is the impact that
Anthos and ExoAnthos have on immunological markers including, but not limited to IL-1β,
IL-4, IL-6, IL-10, IL-17, IFNγ and TNFα. Furthermore, my PhD. work will investigate the
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impact of Anthos on a proposed dialogue between the environmental carcinogen
benzo[a]pyrene and ETBF bacteria using an ApcMin/+ mouse model.
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Peer Teacher First Year Seminar Solving 21st Century Problems: Theory to
Practice, Honors Section
Wilson College, Fall 2007
Worked with faculty member to develop the course, co-taught lectures, and participated
in grading.
Peer Teacher First Year Seminar on Sustainable Living, Honors
Section
Wilson College, Fall 2006
Worked with faculty member from the Biology department to develop the course, co-taught
lectures, and participated in grading.
ACADEMIC AND PROFESSIONAL HONORS:
-University of Louisville 1st place Louisville Women in Medicine and Science Research
Award (Fall 2015)
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-University of Louisville IPIBS Fellowship recipient (Fall 2014-Summer 2016)
-Honors in Chemistry
-Wilson College Davison Greenawalt Grove Award for Distinction in Senior Research in
the Physical and Life Sciences (Spring 2009)
-Wilson College Margaret Strode Haines Award for “outstanding qualities of scholarship,
interest in the humanities and strength of mind, body and spirit” (Spring 2009)
-Phi Beta Kappa honor society
-Wilson College Mary-Eleanor Maule Travel Grant (Spring 2009)
-Grant from the Pennsylvania Academy of Science for my Senior Research project
entitled: An Inquiry into the Existence of a Relationship between β-carotene and
Tetrachloroisophthalonitrile Fungicide Residue levels in D.carota (2008-2009)
-Scholarship to attend the 2008 International Diffuse Reflectance Conference
(IDRC)
-Peer Teacher Recognition Award (Spring 2008)
-Wilson College Mary-Eleanor Maule Travel Grant for Spanish (Spring 2008)
-National Science Foundation SEBCLAR scholarship (Fall 2007)
-Scholarship to attend Mises University at the Ludwig von Mises Institute of Austrian
Economics (Summer 2007)
-Liberty Fund weekend colloquia (Fall 2006-Spring 2009)
-Wilson College Robert Shannon McElwain Prize in Mathematics awarded (Spring 2007)
-Wilson College Organic Chemistry Award (Spring 2007)
-Wilson College Peer Teacher Recognition Award (Spring 2007)
-2006-2007 Intercollegiate Studies Institute Honors Fellow
-Wilson College Phoenix Scholar (2006-2009)
-Wilson College’s Honors Program (2006-2009)
-College Board Advanced Placement Scholar with Distinction (Spring 2005)
-Mercersburg Academy Colonel Wills First Place Prize in the Study of Economics (Spring
2005)
-Maintained Honors-High Honors Academic Status while attending The Mercersburg
Academy (Spring 2005)
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PATENTS:
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Repeat Labeling. U.S. Patent US20140072748 A1 Sept 12, 2013 (Issued March 13, 2014)
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ABSTRACTS/POSTER PRESENTATIONS:
Mudd, A. M., Gu, T., Jeyabalan, J., Munagala, R., Egilmez., N.K., Gupta, R. C. (2017,
March)Prevention and Treatment of Colorectal Cancer by BilberryDerived Anthocyanidin
s (Anthos) and Nano-Anthos. Abstract submitted for poster session at Berry Health
Benefits Symposium, Pismo Beach, CA.
Mudd, A. M., Gu, T., Jeyabalan, J., Munagala, R., Egilmez., N. K., Gupta, R. C. (2016,
October) Prevention and treatment of familial adenomatous polyposis (FAP) and
colorectal cancer by bilberry-derived anthocyanidins Abstract submitted for poster session
at annual Research Louisville, Louisville, KY.
Mudd, A. M., Munagala, R., Gupta, R. C. (2015, October) Exosomal formulations enhance
therapeutic response of anthocyanidins against breast cancer. Abstract submitted for
poster session at annual Research Louisville, Louisville, KY.

Professional Memberships
American Chemical Society
Pennsylvania Academy of Science
Phi Beta Kappa Honor Society
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